Georgiamune to ship preclinical solid tumor drug to Menarini in deal up to $1.1 billion

Georgiamune, a small biotech based in Maryland, announced that it will supply its preclinical solid tumor candidate to Menarini, a family‑owned pharmaceutical company in Italy.

The agreement is structured as a milestone‑driven deal that could total up to $1.1 billion if all development and regulatory targets are met.

The partnership gives Menarini early access to a potential new oncology therapy while providing Georgiamune with substantial upfront and milestone funding to advance the drug's development.

The transaction underscores the growing interest in early‑stage cancer assets and cross‑border collaborations within the pharmaceutical industry.